ORAI3: A Potential Drug Target for Age-Related Conditions (G93129)

Target Name: ORAI3

NCBI ID: G93129

ORAI3

ORAI3: A Potential Drug Target for Age-Related Conditions

ORAI3 (ORAI3_HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The protein is a key regulator of the telomere, which is the protective caps at the end of chromosomes that naturally shorten with age . As telomeres continue to shorten, the risk of age-related diseases increases, and so targeting ORAI3 may provide new treatments for age-related conditions.

ORAI3 is a 21-kDa protein that is expressed in various human tissues, including muscle, liver, and brain. It is a member of the ORAI3 gene family, which is characterized by the presence of a hypervariable region (HVR) in the middle of the gene. The HVR is involved in the regulation of gene expression and has been implicated in various cellular processes, including cell adhesion, migration, and survival.

One of the most significant functions of ORAI3 is its role in regulating telomere length. Telomeres are composed of a repeating sequence and some non-repeating sequences, and their length is constantly being shortened as the cell divides. This process is essential for the maintenance of cellular immortality, as telomeres act as protective caps that prevent cells from aging. As telomeres continue to shorten, the risk of age-related diseases increases, and so targeting ORAI3 may provide new treatments for age-related conditions.

ORAI3 has been shown to play a role in the regulation of telomere length in various human cell lines and primary cells. For example, studies have shown that ORAI3 can shorten telomeres in human immune cells, such as T cells and natural killer cells. This may have implications for the development of cancer therapies that target telomeres. Additionally, ORAI3 has been shown to be involved in the regulation of cellular apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body.

ORAI3 is also involved in the regulation of cell adhesion and migration. This may have implications for the development of therapies that target these processes in cancer. For example, ORAI3 has been shown to be involved in the regulation of cell-cell adhesion in various tissues , including the brain. This may suggest that ORAI3 could be a useful target for therapies that target brain metastases. Additionally, ORAI3 has been shown to be involved in the regulation of cell migration, which may have implications for the development of therapies that target cancer cells.

ORAI3 has also been shown to play a role in the regulation of gene expression. This may have implications for the development of personalized therapies that are tailored to the specific needs of an individual patient. For example, ORAI3 has been shown to be involved in the regulation of gene expression in various tissues, including the brain. This may suggest that ORAI3 could be a useful target for therapies that target gene expression in cancer.

In conclusion, ORAI3 is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The protein is involved in the regulation of telomere length, cell adhesion, and migration, as well as gene expression. Targeting ORAI3 may provide new treatments for age-related conditions and other diseases. Further research is needed to fully understand the role of ORAI3 in these processes and to develop effective therapies that target it.

Protein Name: ORAI Calcium Release-activated Calcium Modulator 3

Functions: Ca(2+) release-activated Ca(2+)-like (CRAC-like) channel subunit which mediates Ca(2+) influx and increase in Ca(2+)-selective current by synergy with the Ca(2+) sensor, STIM1

The "ORAI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ORAI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets